Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis - PubMed (original) (raw)

. 2009 May;75(10):1060-70.

doi: 10.1038/ki.2009.43. Epub 2009 Feb 25.

Affiliations

• PMID: 19242505
• DOI: 10.1038/ki.2009.43

Free article

Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis

Masayuki Iyoda et al. Kidney Int. 2009 May.

Free article

Abstract

Imatinib is a selective tyrosine kinase inhibitor that can block activity of the platelet-derived growth factor receptor (PDGFR) and that has immunomodulatory effects on various cell types. Here we measured the protective effects of imatinib in Wistar-Kyoto rats with nephrotoxic serum nephritis, a kidney disease model where CD8+ T cells and macrophages play pathogenetic roles. Groups of animals were given imatinib from one day before up to 13 days following induction of nephritis and from day 7 to 20 following disease induction. Compared to control rats, at each time point imatinib treatment caused significantly less proteinuria, lowered serum blood urea nitrogen and creatinine, and decreased the number of glomeruli with necrosis, crescents, and fibrin deposits. Imatinib-treated rats had a significant reduction in glomerular macrophage accumulation and reduced renal cortical PDGFR-beta and M-CSF receptor mRNA expression. Using colocalization we found that glomerular macrophages had reduced IL-1beta and MCP-1 protein expression. Late imatinib treatment significantly reduced proteinuria, serum blood urea nitrogen, and creatinine, and reversed renal histopathological changes. We show that imatinib has renoprotective and therapeutic properties and provide pre-clinical work that will need to be confirmed in patients with crescentic glomerulonephritis.

PubMed Disclaimer

Similar articles

• Long- and short-term treatment with imatinib attenuates the development of chronic kidney disease in experimental anti-glomerular basement membrane nephritis.
  Iyoda M, Shibata T, Wada Y, Kuno Y, Shindo-Hirai Y, Matsumoto K, Akizawa T. Iyoda M, et al. Nephrol Dial Transplant. 2013 Mar;28(3):576-84. doi: 10.1093/ndt/gfs414. Epub 2012 Oct 8. Nephrol Dial Transplant. 2013. PMID: 23045430
• Interleukin-4 ameliorates crescentic glomerulonephritis in Wistar Kyoto rats.
  Cook HT, Singh SJ, Wembridge DE, Smith J, Tam FW, Pusey CD. Cook HT, et al. Kidney Int. 1999 Apr;55(4):1319-26. doi: 10.1046/j.1523-1755.1999.00354.x. Kidney Int. 1999. PMID: 10200996
• Treatment with a cyclin-dependent kinase inhibitor, seliciclib, is effective in reducing glomerular macrophage numbers and the severity of established experimental glomerulonephritis.
  Sheryanna AM, Smith J, Bhangal G, Barnett A, McClue S, Tam FW, Cook T, Pusey CD. Sheryanna AM, et al. Nephrology (Carlton). 2011 May;16(4):410-6. doi: 10.1111/j.1440-1797.2010.01416.x. Nephrology (Carlton). 2011. PMID: 21518118
• Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis.
  Khan SB, Cook HT, Bhangal G, Smith J, Tam FW, Pusey CD. Khan SB, et al. Kidney Int. 2005 May;67(5):1812-20. doi: 10.1111/j.1523-1755.2005.00279.x. Kidney Int. 2005. PMID: 15840028
• Important role for macrophages in induction of crescentic anti-GBM glomerulonephritis in WKY rats.
  Isome M, Fujinaka H, Adhikary LP, Kovalenko P, El-Shemi AG, Yoshida Y, Yaoita E, Takeishi T, Takeya M, Naito M, Suzuki H, Yamamoto T. Isome M, et al. Nephrol Dial Transplant. 2004 Dec;19(12):2997-3004. doi: 10.1093/ndt/gfh558. Nephrol Dial Transplant. 2004. PMID: 15574997

Cited by

• Reno-protective effect of IL-34 inhibition on cisplatin-induced nephrotoxicity in mice.
  Wada Y, Iyoda M, Matsumoto K, Suzuki T, Tachibana S, Kanazawa N, Honda H. Wada Y, et al. PLoS One. 2021 Jan 11;16(1):e0245340. doi: 10.1371/journal.pone.0245340. eCollection 2021. PLoS One. 2021. PMID: 33428678 Free PMC article.
• Predictive Value of Precision-Cut Kidney Slices as an Ex Vivo Screening Platform for Therapeutics in Human Renal Fibrosis.
  Bigaeva E, Puerta Cavanzo N, Stribos EGD, de Jong AJ, Biel C, Mutsaers HAM, Jensen MS, Nørregaard R, Leliveld AM, de Jong IJ, Hillebrands JL, van Goor H, Boersema M, Bank RA, Olinga P. Bigaeva E, et al. Pharmaceutics. 2020 May 18;12(5):459. doi: 10.3390/pharmaceutics12050459. Pharmaceutics. 2020. PMID: 32443499 Free PMC article.
• Podocyte Injury in Lupus Nephritis.
  Sakhi H, Moktefi A, Bouachi K, Audard V, Hénique C, Remy P, Ollero M, El Karoui K. Sakhi H, et al. J Clin Med. 2019 Aug 29;8(9):1340. doi: 10.3390/jcm8091340. J Clin Med. 2019. PMID: 31470591 Free PMC article. Review.
• Selective pharmacological inhibition of DDR1 prevents experimentally-induced glomerulonephritis in prevention and therapeutic regime.
  Moll S, Yasui Y, Abed A, Murata T, Shimada H, Maeda A, Fukushima N, Kanamori M, Uhles S, Badi L, Cagarelli T, Formentini I, Drawnel F, Georges G, Bergauer T, Gasser R, Bonfil RD, Fridman R, Richter H, Funk J, Moeller MJ, Chatziantoniou C, Prunotto M. Moll S, et al. J Transl Med. 2018 Jun 1;16(1):148. doi: 10.1186/s12967-018-1524-5. J Transl Med. 2018. PMID: 29859097 Free PMC article.
• A Novel Role of a Chemotherapeutic Agent in a Rat Model of Endotoxemia: Modulation of the STAT-3 Signaling Pathway.
  Zaki OS, Safar MM, Ain-Shoka AA, Rashed LA. Zaki OS, et al. Inflammation. 2018 Feb;41(1):20-32. doi: 10.1007/s10753-017-0659-5. Inflammation. 2018. PMID: 28871508

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal